ValuEngine Downgrades uniQure (QURE) to Sell

uniQure (NASDAQ:QURE) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.

QURE has been the subject of a number of other reports. Zacks Investment Research upgraded uniQure from a “sell” rating to a “hold” rating and set a $9.25 target price for the company in a report on Wednesday, August 9th. Leerink Swann lifted their target price on uniQure from $19.00 to $26.00 in a report on Tuesday, November 7th. Oppenheimer reiterated a “hold” rating on shares of uniQure in a report on Friday, November 24th. HC Wainwright started coverage on uniQure in a report on Friday. They issued a “buy” rating and a $28.00 target price for the company. Finally, Evercore ISI started coverage on uniQure in a report on Tuesday, November 7th. They issued an “outperform” rating and a $22.00 target price for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. uniQure has a consensus rating of “Buy” and a consensus target price of $18.75.

Shares of uniQure (NASDAQ QURE) opened at $15.56 on Friday. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.64 and a quick ratio of 3.64. uniQure has a 1-year low of $4.72 and a 1-year high of $21.35.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of uniQure by 4.1% during the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after acquiring an additional 61,650 shares in the last quarter. Morgan Stanley increased its holdings in shares of uniQure by 14.9% during the first quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock valued at $3,271,000 after acquiring an additional 73,418 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of uniQure by 48.8% during the first quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock valued at $2,162,000 after acquiring an additional 122,700 shares in the last quarter. Mangrove Partners increased its holdings in shares of uniQure by 167.4% during the third quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock valued at $1,024,000 after acquiring an additional 66,763 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of uniQure by 33.5% during the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after acquiring an additional 14,659 shares in the last quarter. Hedge funds and other institutional investors own 24.87% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2017/12/03/valuengine-downgrades-uniqure-qure-to-sell.html.

uniQure Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Analyst Recommendations for uniQure (NASDAQ:QURE)

What are top analysts saying about uniQure N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for uniQure N.V. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit